Thanks to a deep understanding of metabolic disorders and physiopathology, LNC Therapeutics develops gut microbiota directed drugs to tackle obesity and its associated cardiometabolic diseases

LNC LNC Therapeutics is working on the first gut microbiota directed drugs initiated by a medical nutrition product clinical outcomes

Our solutions for metabolic diseases

Medical Nutrition Product
Gut microbiota directed drugs
Who benefits


Public Health

Pharmaceutical groups

Human gut microbiome is a revolutionary field presenting numerous promising opportunities in obesity management

about us

From the creation of LNC Therapeutics, the founders shared the same vision: to address the issue of obesity by acting on its fundamental causes

Learn more

In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials

Discover our selection

Find out more
LNC Therapeutics acquires...
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and...
LNC Therapeutics launches a new...
Bordeaux, October 1st, 2018 – LNC Therapeutics, a French biotech company specialized in the...
Christensenella: the...
LNC Therapeutics, a French biotechnology company specialized in research and development for gut...
Obésité, des alternatives à...
La connaissance de notre flore intestinale, de nos gènes et de notre cerveau laissent entrevoir de...